Pharmather Holdings Ltd. (OTCQB: PHRRF) reported financial results for its third quarter ended February 28, 2022.
Financial Results
Cash and cash equivalents totaled CA$10,165,170 ($7,955,803) and investment totaled CA$1,666,667 ($1,304,422) for a total of CA$11,831,837 ($9,260,226) as of February 28, 2022.
Accounts payable and accrued liabilities totaled CA$140,947 ($110,312) as of February 28, 2022.
Recent Highlights
The company received an Orphan Drug Designation for a ketamine-based medicine for treating an epileptic condition.
Received approval from the FDA to proceed with a Phase 2 clinical trial for an Amyotrophic Lateral Sclerosis treatment.
The company entered into collaborative research with Revive Therapeutics (OTCQB: RVVTF) to develop a psilocybin microneedle patch. Pharmather is also developing microneedle patches for administering ketamine (along with LTS Lohmann Therapie-Systeme AG) and another one for administering LSD.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving – don’t get left behind!
Curious about what’s next for the industry and how to leverage California’s unique market?
Join top executives, policymakers, and investors at the Benzinga Cannabis Market Spotlight in Anaheim, CA, at the House of Blues on November 12. Dive deep into the latest strategies, investment trends, and brand insights that are shaping the future of cannabis!
Get your tickets now to secure your spot and avoid last-minute price hikes.